Skip to main content
. 2008 Aug 11;105(33):11915–11920. doi: 10.1073/pnas.0805434105

Fig. 5.

Fig. 5.

Pharmacology of PCSK9 silencing in NHPs. (A) Direct LDLc measurements of serum from cynomolgus monkeys treated with 5 mg/kg LNP-PCS-A2 (n = 5 per group), LNP-PCS-B2 (n = 4 per group), or PBS (n = 3 per group). (B) Total cholesterol/HDL ratios as measured in the samples described in A. (C) Plasma samples from the treatment groups in A were analyzed for their levels of PCSK9 protein by ELISA. Values for LDLc, Tc/HDLc, and PCSK9 concentrations were graphed as a ratio of the average values of after dose compared with predose values within an animal. Those values were then combined into group averages. (A–C) LNP-Crtl behaved similarly on d4 and d7 as PBS (data not shown). PBS values are the mean of the groups ± STDEV averaged over days 3–14. Each value represents the mean of the group ± STDEV. Two-way ANOVA with Bonferroni test was used. Asterisks represent statistical difference between PBS- and PCSK9 siRNA-treated groups. **, P ≤ 0.01; ***, P ≤ 0.001.